Evidence map›Paper›PMID 28439106›Full record

Trial reportLeukemia2017

Lenalidomide, adriamycin, dexamethasone for induction followed by stem-cell transplant in newly diagnosed myeloma.

S Knop, C Langer, M Engelhardt, L-O Mügge, A Reichle, W Rösler, F Bassermann, B Hertenstein, A Kunitz, C Röllig and 11 more

Abstract readClinical Trial, Phase IILetter
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

S KnopDivision of Hematology and Medical Oncology, Würzburg University Medical Center, Würzburg, Germany.
C LangerDepartment of Internal Medicine III, University of Ulm, Ulm, Germany.
M EngelhardtDepartment of Hematology and Oncology, University of Freiburg Medical Center, Freiburg, Germany.
L-O MüggeHematology and Oncology, Jena University Hospital, Jena, Germany.
A ReichleDepartment of Hematology and Medical Oncology, University of Regensburg, Regensburg, Germany.
W RöslerHematology and Oncology, Erlangen University Hospital, Erlangen, Germany.
F BassermannDepartment of Hematology and Oncology, University Hospital Rechts der Isar, Munich, Germany.
B HertensteinHematology and Oncology, Bremen-Mitte Clinic, Bremen, Germany.
A KunitzHematology and Oncology, Charité Campus Virchow, Berlin, Germany.
C RölligDepartment of Internal Medicine I, University Hospital Carl Gustav Carus Dresden, Dresden, Germany.
H OstermannDepartment of Hematology, University Hospital Großhadern, Munich, Germany.
K Schäfer-EckartMedical Center, Nürnberg Nord Hospital, Nürnberg, Germany.
M RinghofferThird Department of Medicine, Karlsruhe Hospital, Karlsruhe, Germany.
A GüntherSecond Department of Medicine, Division of Stem Cell Transplantation and Immunotherapy, University of Kiel, Kiel, Germany.
C JunghanssDepartment of Medicine, Clinic III (Hematology/Oncology/Palliative Care), University Medical Center, Rostock, Germany.
H BiersackHematology and Oncology, Schleswig-Holstein University Hospital, Lübeck, Germany.
M SchrederDivision of Hematology and Medical Oncology, Würzburg University Medical Center, Würzburg, Germany.
A LiebertClinAssess GmbH, Leverkusen, Germany.
S HeldClinAssess GmbH, Leverkusen, Germany.
H EinseleDivision of Hematology and Medical Oncology, Würzburg University Medical Center, Würzburg, Germany.
R C BargouDivision of Hematology and Medical Oncology, Würzburg University Medical Center, Würzburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationInduction ChemotherapyAdolescentAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCombined Modality TherapyDexamethasoneDoxorubicinFemaleHumansLenalidomideMaleMiddle AgedMultiple MyelomaSurvival AnalysisDexamethasoneDoxorubicinLenalidomideThalidomide

Identifiers

PMID28439106

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.